ABUS

4.62

6.21% 0.27

Handel nachbörslich: 4.62

Arbutus Biopharma Corp (ABUS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$4.35

Offen:

$4.36

24-Stunden-Volumen:

2.12M

Relative Volume:

1.01

Marktkapitalisierung:

$916.57M

Einnahmen:

$14.08M

Nettoeinkommen (Verlust:

$-33.50M

KGV:

-26.34

EPS:

-0.1754

Netto-Cashflow:

$-39.72M

1W Leistung:

+10.00%

1M Leistung:

+10.00%

6M Leistung:

+4.76%

1J Leistung:

+43.48%

1-Tages-Spanne:

$4.342

$4.64

1-Wochen-Bereich:

$4.19

$4.61

52-Wochen-Spanne:

$3.04

$5.10

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Firmenname

Arbutus Biopharma Corp

Sektor

Healthcare (1113)

Branche

Biotechnology (618)

Telefon

604-419-3200

Adresse

701 VETERANS CIRCLE, WARMINSTER, PA

Mitarbeiter

Twitter

@arbutusbio

Nächster Verdiensttermin

2026-05-13

Neueste SEC-Einreichungen

ABUS's Discussions on Twitter

Compare ABUS vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ABUS Arbutus Biopharma Corp	4.64	859.29M	14.08M	-33.50M	-39.72M	-0.1754
VRTX Vertex Pharmaceuticals Inc	435.92	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.42	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.61	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-02-02	Hochstufung	Jefferies	Hold → Buy
2021-02-25	Eingeleitet	Jefferies	Hold
2020-12-17	Eingeleitet	H.C. Wainwright	Buy
2020-07-27	Fortgesetzt	JMP Securities	Mkt Outperform
2020-07-24	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-05-19	Hochstufung	Wedbush	Neutral → Outperform
2020-03-06	Hochstufung	Chardan Capital Markets	Neutral → Buy
2020-02-20	Eingeleitet	Robert W. Baird	Outperform
2020-02-05	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2019-10-07	Bestätigt	B. Riley FBR	Buy
2019-10-04	Herabstufung	Chardan Capital Markets	Buy → Neutral
2018-10-16	Hochstufung	B. Riley FBR	Neutral → Buy
2018-10-15	Hochstufung	Wedbush	Underperform → Neutral
2018-10-12	Bestätigt	Chardan Capital Markets	Buy
2018-07-06	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-03-19	Fortgesetzt	Chardan Capital Markets	Buy
2018-03-19	Herabstufung	Wedbush	Outperform → Neutral
2018-01-05	Eingeleitet	B. Riley FBR, Inc.	Buy
2017-04-04	Hochstufung	Chardan Capital Markets	Neutral → Buy
2017-02-01	Bestätigt	Wedbush	Outperform
2016-12-13	Herabstufung	Chardan Capital Markets	Buy → Neutral
2016-11-30	Hochstufung	Chardan Capital Markets	Neutral → Buy

Alle ansehen

Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten

May 22, 2026

Arbutus Posts Profit After Moderna Patent Settlement - MyChesCo

May 22, 2026

ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill

May 22, 2026

May 15, 2026

Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan

May 15, 2026

May 13, 2026

Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart

May 13, 2026

Arbutus Biopharma Corporation 8-K Filing: Company Details, Financial Data, and NASDAQ Listing (May 2026) - Minichart

May 13, 2026

Is Arbutus Biopharma (ABUS) Overvalued After Q1 2026 Earnings Be - GuruFocus

May 13, 2026

Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 E - GuruFocus

May 13, 2026

Arbutus Biopharma Corp reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2026

Arbutus Biopharma earnings beat by $0.91, revenue topped estimates - Investing.com

May 13, 2026

Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87— 10-Q Summary - TradingView

May 13, 2026

Arbutus: Q1 Earnings Snapshot - 10TV

May 13, 2026

Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan

May 13, 2026

Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge - Stock Titan

May 13, 2026

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - Stock Titan

May 13, 2026

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS) - Seeking Alpha

May 13, 2026

May 10, 2026

MSN Money - MSN

May 10, 2026

May 08, 2026

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Exploring a 20% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

May 08, 2026

May 06, 2026

Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

May 06, 2026

May 01, 2026

Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey

May 01, 2026

Apr 30, 2026

5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey

Apr 30, 2026

Apr 28, 2026

Whitefort lifts Arbutus (ABUS) economic stake to 9.8% - Stock Titan

Apr 28, 2026

Apr 24, 2026

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat

Apr 24, 2026

Apr 23, 2026

FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -

Apr 21, 2026

Apr 20, 2026

Arbutus (ABUS) Stock: Stability Assessment (Momentum Fading) 2026-04-20Trending Momentum Stocks - newser.com

Apr 20, 2026

Apr 18, 2026

Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN

Apr 18, 2026

Apr 17, 2026

Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Insider Monkey

Apr 17, 2026

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm

Apr 17, 2026

Apr 16, 2026

Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus

Apr 16, 2026

Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 16, 2026

Apr 15, 2026

Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus

Apr 15, 2026